May 3, 2023, 09:08 by ASAM Weekly Editors

The Hedonic Amplification of Feeding

Apr 26, 2023, 12:18 by ASAM Weekly Editors

Opioid Prescribing and Suicide Risk in the US

Apr 19, 2023, 11:03 by ASAM Weekly Editors

Association Between Daily Alcohol Intake and Risk of All-Cause Mortality

Apr 18, 2023, 06:52 by Molly McGrath

On April 17th, ASAM joined 125 other organization in endorsing the Reentry Act, which would allow incarcerated individuals to receive medical services supported by Medicaid thirty days prior to the individual's release and is currently prohibited by the Medicaid Inmate Exclusion Policy (MIEP).

Apr 17, 2023, 11:01 by Maciek Gregorski

The American Society of Addiction Medicine (ASAM) proudly announces its new Board of Directors for the 2023-2025 term

Apr 14, 2023, 12:02 by Molly McGrath

Apr 12, 2023, 09:27 by ASAM Weekly Editors

Genetic Liability for Alcohol Consumption, Alcohol Problems and Suicide Attempts

Apr 10, 2023, 15:40 by Molly McGrath

On April 10th, the Northern New England Society of Addiction Medicine (NNESAM) sent a letter to members of the Maine Legislature’s Joint Committee on Health and Human Services in support of LD 1159.

Apr 5, 2023, 10:59 by ASAM Weekly Editors

Genetic Loci Underlying Multiple Substance Use Disorders

Mar 29, 2023, 17:25 by Molly McGrath

On March 29th, ASAM provided comments to the Office of National Drug Control Policy (ONDCP). recommending it include actions in the 2024 biennial national drug control strategy that call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.

Mar 29, 2023, 14:46 by Molly McGrath

On March 27th, the Arkansas Society of Addiction Medicine (ARSAM) sent a letter to members of the Senate Committee on Insurance and Commerce expressing support for removing prior authorization on injectable medications for addiction treatment (MAT) and proposing improvements to strengthen the provisions of HB 1558.

Mar 29, 2023, 09:20 by ASAM Weekly Editors

Human brain effects of DMT assessed via EEG-fMRI

Mar 27, 2023, 18:32 by Molly McGrath

On March 27th, ASAM provided comments to the Drug Enforcement Administration's (DEA) notice of proposed rulemaking (NPRM) regarding the expansion of induction of buprenorphine via telemedicine encounter.

Mar 24, 2023, 11:52 by Molly McGrath

On March 24th, the Kentucky Society of Addiction Medicine (KYSAM) sent a letter to members of Senate Committee of Health Services supporting HB 353.

Mar 23, 2023, 15:32 by Molly McGrath

On March 23rd, ASAM signed onto a letter with dozens of organizations, sent to Chairs and Ranking Members of the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the of the U.S. House and Senate Appropriations Committees, urging them to increase funding for important addiction prevention, treatment, harm reduction, and recovery support programs.

Mar 22, 2023, 09:18 by ASAM Weekly Editors

Fatal Poisonings Among Infants and Young Children in the United States

Mar 21, 2023, 16:12 by Molly McGrath

On March 16th, ASAM signed onto letters to the U.S. House and Senate Chairs and Ranking Members of the Committee on Appropriation's Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, urging them to increase funding for the Centers for Disease Control and Prevention's (CDC) Office on Smoking and Health (OSH).

Mar 17, 2023, 14:31 by Molly McGrath

On March 17th, ASAM sent a letter to the U.S. Senate Committee on Health, Environment, Labor, and Pensions' (HELP), in response to its request for information on solutions to the nation's healthcare workforce shortages.

Mar 15, 2023, 13:16 by Molly McGrath

On March 15th, the Tennessee Society of Addiction Medicine (TNSAM) sent a letter to members of the Senate Committee on Health and Welfare expressing concern with HB665/SB733.

Mar 15, 2023, 10:11 by ASAM Weekly Editors

Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment